Adial Pharmaceuticals (ADIL) Competitors $0.35 -0.02 (-6.42%) Closing price 04:00 PM EasternExtended Trading$0.35 0.00 (-0.57%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADIL vs. RNTX, MAAQ, RVPH, ITRM, KZR, CLSD, ASBP, CASI, PMN, and TENXShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Rein Therapeutics (RNTX), Mana Capital Acquisition (MAAQ), Reviva Pharmaceuticals (RVPH), Iterum Therapeutics (ITRM), Kezar Life Sciences (KZR), Clearside Biomedical (CLSD), Aspire Biopharma (ASBP), CASI Pharmaceuticals (CASI), Promis Neurosciences (PMN), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Its Competitors Rein Therapeutics Mana Capital Acquisition Reviva Pharmaceuticals Iterum Therapeutics Kezar Life Sciences Clearside Biomedical Aspire Biopharma CASI Pharmaceuticals Promis Neurosciences Tenax Therapeutics Rein Therapeutics (NASDAQ:RNTX) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation. Do analysts prefer RNTX or ADIL? Adial Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 2,185.71%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Adial Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, RNTX or ADIL? Rein Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Is RNTX or ADIL more profitable? Rein Therapeutics' return on equity of -141.11% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -141.11% -33.83% Adial Pharmaceuticals N/A -191.31%-153.59% Do insiders and institutionals have more ownership in RNTX or ADIL? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by company insiders. Comparatively, 4.3% of Adial Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor RNTX or ADIL? In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Rein Therapeutics. MarketBeat recorded 5 mentions for Adial Pharmaceuticals and 1 mentions for Rein Therapeutics. Adial Pharmaceuticals' average media sentiment score of 0.75 beat Rein Therapeutics' score of 0.59 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adial Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, RNTX or ADIL? Rein Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.69-0.51Adial PharmaceuticalsN/AN/A-$13.20M-$1.05-0.33 SummaryAdial Pharmaceuticals beats Rein Therapeutics on 9 of the 14 factors compared between the two stocks. Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.16M$222.22M$5.76B$9.85BDividend YieldN/A3.78%6.71%4.51%P/E Ratio-0.3341.9959.1122.53Price / SalesN/A4,954.73547.00119.09Price / CashN/A13.1937.0558.92Price / Book0.5576.1510.916.06Net Income-$13.20M-$90.99M$3.29B$266.28M7 Day Performance-9.98%1.84%0.01%-0.76%1 Month Performance-15.74%15.69%7.06%3.83%1 Year Performance-66.35%412.27%50.09%24.39% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals2.8704 of 5 stars$0.35-6.4%$8.00+2,185.7%-62.6%$8.16MN/A-0.3320News CoverageShort Interest ↓Gap DownRNTXRein TherapeuticsN/A$1.39+23.0%N/AN/A$32.39MN/A-0.529News CoveragePositive NewsGap UpHigh Trading VolumeMAAQMana Capital AcquisitionN/A$3.81+0.5%N/A+937.3%$30.96MN/A0.001Gap DownRVPHReviva Pharmaceuticals2.3797 of 5 stars$0.45-2.2%$5.20+1,055.6%-62.9%$30.60MN/A-0.695ITRMIterum Therapeutics3.2433 of 5 stars$0.68-2.2%$9.00+1,229.8%-44.3%$30.22MN/A-0.8010Positive NewsShort Interest ↓KZRKezar Life Sciences2.7867 of 5 stars$3.95-0.5%$9.00+127.8%-32.9%$28.93MN/A-0.4160CLSDClearside Biomedical2.3641 of 5 stars$0.37-5.1%$4.20+1,042.9%-66.0%$28.85M$1.66M-0.9930Gap DownHigh Trading VolumeASBPAspire BiopharmaN/A$0.58+3.4%N/AN/A$28.50MN/A0.00N/ANews CoverageCASICASI Pharmaceuticals3.6813 of 5 stars$2.31-5.3%$4.00+73.2%-64.2%$28.41M$28.54M-0.80180Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionPMNPromis Neurosciences2.8113 of 5 stars$0.54+2.7%$4.33+702.6%-64.9%$27.97MN/A-2.575News CoverageTENXTenax Therapeutics1.3616 of 5 stars$5.99+1.0%$17.00+183.8%+56.0%$27.31MN/A-6.519 Related Companies and Tools Related Companies Rein Therapeutics Alternatives Mana Capital Acquisition Alternatives Reviva Pharmaceuticals Alternatives Iterum Therapeutics Alternatives Kezar Life Sciences Alternatives Clearside Biomedical Alternatives Aspire Biopharma Alternatives CASI Pharmaceuticals Alternatives Promis Neurosciences Alternatives Tenax Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADIL) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
